spacer
home > ebr > spring 2002 > preclinical and clinical evaluation of therapeutic vaccines - 21st-22nd january 2002, london
PUBLICATIONS
European Biopharmaceutical Review

Preclinical and Clinical Evaluation of Therapeutic Vaccines - 21st-22nd January 2002, London

Since as long ago as the 1890s, when William Coley used streptococcal cultures to treat patients with advanced sarcoma, it has been known that the immune system can be prompted to attack cancer cells. More recently, melanoma tumours in animals have been shown to regress when injected with modified autologous cancer cells primed to stimulate an immune response. And now, somewhat like the resurgence of interest surrounding recent therapeutic success with monoclonal antibodies, the concept of stimulating the immune system to recognise and destroy foreign or indeed tumour cells, so-called 'therapeutic vaccines', is, it seems, again in vogue.This kind of technology is distinct from normal vaccination in that the patient already has the disease or condition before the vaccine is given. For any number of reasons, the patient has not already responded to the disease-associated antigens - possibly because they are 'self'-antigens (on endogenous cells such as tumour cells), or they are hidden from the immune response by directly disrupting or affecting immune cell function (HIV).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Helen Abbott and Dr Keith Chidwick of Technomark Consulting Services Limited
spacer
Dr Helen Abbott
spacer
spacer
spacer
Dr Keith Chidwick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Environmental Factors in Data Centres

Dycem

In addition to temperature and humidity, there are many more constraints in the environment that increase failure rates, explains Emilio Sapiña of Secure Techincal Rooms.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement